A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Description

The study is a Phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors.

Conditions

Advanced Solid Tumors

Talk to us

Study Overview

On this page

Study Details

Study overview

The study is a Phase 1dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors.

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 as a Single Agent in Patients With Selected Advanced Solid Tumors.

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Condition
Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Irving Medical Center, New York, New York, United States, 10032

Pittsburgh

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
  • 2. ECOG performance status of ≤ 2.
  • 3. Life expectancy of ≥ 3 months.
  • 4. The results of the laboratory tests must meet all criteria.
  • 1. Patients have received antitumor therapy during the first 4 weeks before study drug use.
  • 2. Received a live attenuated vaccine within 4 weeks prior to C1D1.
  • 3. Known cerebral parenchymal metastasis or meningeal metastasis.
  • 4. History of serious cardiovascular or cerebrovascular diseases.
  • 5. Active or recurrent autoimmune diseases.
  • 6. History of ascites or pleural effusion requiring drainage.
  • 7. Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AskGene Pharma, Inc.,

Barbara Hickingbottom, MD, STUDY_DIRECTOR, Ask-Gene Pharma, Inc.

Study Record Dates

2025-12